ChoA Pharmaceutical Responds to Exchange Inquiry, Confirms No Material Information, Limited Stock Price Impact

ChoA Pharmaceutical responded on June 24, 2026 to the Korea Exchange's inquiry regarding unusual market movements, stating that there is no material information to disclose.
This response is intended to alleviate market concerns about recent stock price and volume fluctuations. The company explicitly stated that no matters are under review based on KOSDAQ disclosure regulations.
The reply signed by Managing Director Lee Hyun-jin indicates no capital changes or management alterations, implying a neutral short-term impact on the stock price.
[AI Summary]ChoA Pharmaceutical's response to the exchange inquiry confirms the absence of material information. With no capital or governance changes, the impact on shareholder value is neutral. Investors should monitor for future disclosures.